INS and Insulin resistance: Insulin resistance, a known side effect of GC therapy, contributes to muscle atrophy via reduced protein synthesis and increased protein degradation by genomic and non-genomic interference with several kinases in the insulin-signaling pathway [29,38,39,40,41,42,43].